

Curriculum vitae (short version): *Hans-Henrik Parving, Professor, Chief Physician, M.D., DMSc., Department of Endocrinology, National Hospital, University of Copenhagen, Denmark.*

Dr. Hans-Henrik Parving (HHP) was born in Denmark in 1943. Attended The Medical School at the University of Copenhagen and graduated in 1969. In 1975 he defended his thesis 'Microvascular permeability to plasma proteins in hypertension and diabetes in man - on the pathogenesis of hypertensive and diabetic microangiopathy' (University of Copenhagen).

In 2005 HHP was knighted by Queen Margrethe II of Denmark.

Trained at different university hospitals in Copenhagen (1969-1983), and specialised in internal medicine (1977) and in endocrinology (1984) at the University of Copenhagen. Chief physician at Steno Diabetes Center since 1983 -2006. Chief physician Department of Medical Endocrinology, National hospital, University of Copenhagen 2007-. Since 1997 appointed professor of diabetic vascular diabetic complications (personal chair) at the University of Aarhus, Denmark. Since 2010 appointed professor of diabetic complications (personal chair) at the University of Copenhagen, Denmark.

HHP Has published more than 650 peer-reviewed papers and 100 reviews and text-book chapters. Twentyone research fellows have defended their doctoral thesis (DMSc) from HHP's lab. HHP has made important contributions in international postgraduate courses in diabetes.

Since 1975 HHP has focused on studies of diabetic micro- and macroangiopathy. The natural history of diabetic micro- and macroangiopathy was described in large observational studies. The life saving importance of early intensive antihypertensive treatment in diabetic nephropathy was demonstrated. Moreover, the importance of microalbuminuria as a risk marker for development of diabetic kidney disease was reported.. Prevention and treatment of diabetic nephropathy in type 1 patients using ACE and non-ACE inhibitors were evaluated in several randomised prospective studies. In The Steno Type 2 study we demonstrated that intensified multifactorial

intervention delays the progression of microvascular and macrovascular complications - including heart failure and stroke - and improved prognosis in high-risk patients with Type 2 diabetes mellitus and microalbuminuria. Prevention of diabetic nephropathy and protection against end stage renal disease in Type 2 diabetic patients were documented using angiotensin II receptor antagonist. The beneficial impact on kidney function and survival of drug induced remission in diabetic kidney documented in Type 1 and 2 diabetic patients.

HHP has served as chairman or member of national and international boards of scientific societies, councils and multinational treatment investigations concerning prevention and treatment of renal and cardiovascular disease.

HHP has received several national and international awards including the prestigious Castelli Pedroli prize, awarded EASD , and the Novartis award in diabetes- longstanding achievement to recognise his accompaniments in pathogenesis early detection, prevention and treatment of vascular complications in diabetes mellitus. “The standing foreign investigator award “ Japanese society of diabetic complications. The Belding H. Scribner Award, American Society of Nephrology. B.G. Morgagni Gold Medal Prize.